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Neurodegeneration diseases (NDD) are 
progressing neuropsychological disorders. Dia­
betes mellitus (DM) plays an important role 
among its causes. In spite of the lack of suf­
ficient amount of scientifically based evidences 
which are indicative of a close relation between 
DM and neurodegeneration, there is an opinion 
that this pathology produces a negative effect 
on the cerebral metabolism, promotes cerebral 
atrophy and accelerates brain aging. Decrease 
of cognitive functions is known to be one of the 
main complications of DM. At the same time 
this disease is one of the risk factors promoting 
development of Alzheimer’s disease — one of 
the most spread diseases of neurodegenerative 
character [1].
High energy requirements make the brain 
especially sensitive to glucose metabolism. 
Deficiency of glucose availability and mito­
chondrial dysfunction are well known signs of 
brain aging, and they are especially intensified 
in case of NDD, such as Alzheimer’s disease. 
At the same time, in case of Alzheimer’s di­
sease much lower levels of glucose metabolism 
and pathological processes are found associated 
with decreased sensitivity of cerebral neurons 
to insulin. 
Insulin resistance decreases glucose meta­
bolism resulting in hyperphosphorylation of 
tau­protein promoting formation of neurofibril­
lary glomeruli (protein accumulation in a modi­
fied form) and NDD progress. Moreover, neu­
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rodegeneration is intensified by DM, and by 
hyperglycemia in particular [2].
One of the main causes of memory dete­
rioration is not only hyperglycemia but insuf­
ficient amount of sugar in the brain, where its 
deficiency is found in case of DM­2, which is 
evidenced by experimental and clinical investi­
gations [3]. The majority of anti­diabetic agents 
produce a positive effect in case of DM, though 
an optimal glycemia level is achieved in the 
minority of patients, which requires additional 
pharmacological agents. Moreover, existence of 
«hyperglycemic» memory gives the grounds to 
suggest that the majority of patients can lose 
their sensitivity to control an optimal glucose 
level after a long period of its uncontrolled 
increase [4].
Nowadays an active search of effective 
pharmacological agents is being conducted 
concerning preventive therapy and treatment 
of NDD. It is worth noting that with glucose 
metabolism it remains a functional cycle of 
gamma­aminobutyric acid (GABA) [5, 6]. In 
addition, dysglycemia uses the functional ac­
tivity of GABA, a universal neurotransmitter 
of the central nervous system (CNS), due to 
which there is a constant inhibition and devel­
opment, energy supply, cognitive functions [7].
Considering the above, investigation of the ef­
ficacy of carbacetam, as a new GABA modula­
tor, seems to be topical [8] under conditions of 
development of neurodegenerative changes in 
case of DM. 
The circulating (systemic) and tissue (ce­
rebral) renin­angiotensin system (RAS) par­
ticipate in pathogenesis of cognitive disorders. 
RAS blockers, that is, angiotensin conver ting 
enzyme inhibitors (ACEI), are known to de­
crease hippocampus apoptosis in case of cere­
bral ischemia, and improve spatial learning 
and memory considerably [9]. Though nowa­
days ACEI are considered to be as means of 
prevention and treatment of DM complications, 
their role as GABA modulators in case of devel­
opment of central diabetic neurodegeneration 
is not determined exactly. The neuroprotective 
efficacy of ACEI in scopolamine­induced CNS 
damage was experimentally established [10], 
which led to the use of ACEF enalapril under 
the combination of diabetes and central neuro­
degeneration in our study. 
Objective: to assess efficacy of pharmaco­
logical correction of cognitive disorders by car­
bacetam, GABA modulator, and enalapril, RAS 
blocker, in case of experimental neurodegenera­
tion caused by type 2 DM.
MATERIALS AND METHODS
The experiments were conducted on male 
rats 0,18–0,20 kg of the body weight kept un der 
conditions of natural light, temperature and 
air humidity according to vivarium standards. 
The research was performed in accordance 
with European Convention for the Protection of 
Vertebrate Animals used for Experimental and 
other Scientific Purposes (Strasburg, 1986).
Type 2 DM model was simulated by means 
of intraperitoneal (i/p) injection of streptozoto­
cin (STZ) in the dose of 30 mg/kg on the citrate 
buffer (рН = 4,5) given to rats kept on high­fat 
diet during 30 days, with free access to fruc­
tose solution (200 g/L) [11]. The control group of 
rats kept on standard forage and free access to 
water was given citrate buffer i/p. Reproduction 
of type 2 DM was evidenced on the 7th day after 
STZ injection by means of detection of glucose 
concentration in the blood plasma on empty 
stomach. Rats with hyperglycemia lower than 
10 mmol/L were excluded from the experiment. 
On the 11th week after STZ injection the 
rats were divided into three groups by means 
of randomized method: I — with i/p adminis­
tration of carbacetam in the dose of 5 mg/kg; 
II — with i/p administration of enalapril in the 
dose of 1 mg/kg; III — with administration of 
phy siological solution (saline). 
The control group of rats during the whole 
period of correction (14 days) received saline 
only.
Cognitive ability of rats was assessed by 
the indices of tests «open field» and «the con­
ditional reflex reaction of passive avoidance» 
(CRPA) [12–14]. Anti­amnestic activity (AA) 
was calculated by means of Butler formula [15]: 
АА = (ΔLPP – ΔLPС) / (ΔLPІ – ΔLPС) × 100 (%), 
ΔLP — difference of latent period (LP) of en­
trance to a dark camera during studying and 
reproduction of CRPA for the examined speci­
men ΔLPP; simulated pathology (ΔLPС); the 
control group (ΔLPІ). 
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The results were statistically processed 
by means of Student t­criterion. At the same 
time, Mann­Whitney criterion was used, which 
showed similar results. Transformations were 
considered to be reliable with р ≤ 0,05. 
RESULTS AND THEIR DISCUSSION
To verify manifesting type 2 DM we have 
examined glycemic dynamics. The glucose 
level in DM rats on the 10th week after Stz 
administration was 11,99 ± 1,562 mmol/L, 
against 4,87 ± 0,713 mmol/L in the control 
(р < 0,05). Attention is paid to the fact that 
in comparison with the group without cor­
rection, on the 14th day of carbacetam and 
enalapril administration reliable changes 
of the parame ter were not found. Thus, glu­
cose concentration in untreated rats was 
12,01 ± 1,654 mmol/L, in the group with car­
bacetam — 9,94 ± 0,932 mmol/L, in rats recei­
ving enalapril — 10,92 ± 0,976 mmol/L.
The «open field» test of mnestic functions 
analysis showed that in rats with DM type 2 
LP adaptation increased on 53.4 % compared 
with the control group (Table 1). In rats receiv­
ing carbacetam this index 24,1 % reduced, and 
with enalapril administration it did not differ 
from the value of simulated pathology. Since 
the characteristics of the test are light open 
space and new surroundings, certain exertion 
and behavioral changes of rats manifested by 
increased LP of adaptation in rats with type 2 
DM are indicative of an increased degree of 
risk: confusion, fear, disorientation in strange 
surroundings. At the same time, LP decrease, 
this interval of immobility, was peculiar for 
rats with type 2 DM after carbacetam injec­
tion, which is indicative of activation of natural 
adaptive reactions to unusual conditions.
Motor activity of rats with type 2 DM re­
duced: the number of crossed squares 37,9 % 
decreased. After carbacetam administration 
this index 33,9 % and 31,9 % increased — after 
enalapril administration, which is indicative of 
improvement of horizontal motor activity due to 
inhibition of psychological anxiety of rats with 
neurodegeneration of diabetic genesis.
Table 1
Effect of carbacetam and enalapril on the motor,  
oriented-learning and emotional activity of rats with type 2 diabetes mellitus  
in «open field» test, М ± m











(adaptation time), с 10,43 ± 1,51 16,00 ± 1,00* 12,14 ± 0,90** 14,71 ± 1,11*
Motor activity
Number of crossed 
squares 23,00  ±  1,83 14,29 ± 1,11* 19,14 ± 1,22** 18,86 ± 1,22**
Orientation­learning activity
Positions 9,29 ± 1,11 3,57 ± 0,79* 8,29 ± 1,11** 9,00 ± 1,16**
Openings 12,57 ± 0,98 7,00 ± 0,82* 10,29 ± 1,11** 9,00 ± 0,82*
Emotional reactions
Grooming 7,86 ± 0,69 3,14 ± 0,69* 5,57 ± 0,82*,** 6,14 ± 0,69**
Urination 4,14 ± 0,69 2,00 ± 0,58* 1,71 ± 0,76 4,00 ± 0,58**
Fecal bolus 3,71 ± 0,76 1,14 ± 0,38* 1,86 ± 0,69 3,43 ± 0,54**
Reliability: 
* in comparison with the control group; 
** in comparison with the group of rats with type 2 DM.
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The variant of oriented­learning behavior 
of rats is frequency of their upright postures 
(rising on hind legs) and examined holes. In 
comparison with the control group in rats with 
type 2 DM the frequency of upright 65,6 % 
decreased and the amount of the examined 
holes — 44,3 %. The obtained results are indic­
ative of activation of inhibition processes in the 
CNS of rats with DM. Under carbacetam effect 
the above indices 2,3 and 1,5 times increased 
respectively. Meanwhile, enalapril administra­
tion caused 2,5 times increase of upright motor 
activity only compared with the rats from the 
group of simulated pathology.
The results obtained give evidence about 
ability of both drugs to reduce anxiety level and 
improve cognitive activity of rats with DM. At 
the same time, carbacetam improves both hori­
zontal and vertical motor activity, and enala­
pril — vertical one only. One of the important 
characteristics in behavior of experimental 
animals in «open field» is emotional reactions 
(Table 1). Grooming — cosmetic behavior — 
a sign of both comfort and stressful situation, 
was characterized by 60 % decreased number 
of washing in rats with DM. Under carbace­
tam effect grooming sign 77 % increased, and 
after enalapril administration it increased to 
96 % compared with the value in rats with DM. 
Further analysis of vegetative behavior did not 
find changes in the amount of urination and 
fecal boluses with carbacetam use, which in 
general it enables to suggest the absence of its 
important effect on the emotional level of rats 
with DM under conditions of the experiment. 
At the same time, enalapril administration pro­
moted increase of urination and fecal boluses 
2 and 3 times respectively in comparison with 
the simulated rats.
Assessment of cognitive ability according 
to CRPA test showed that in the control rats 
a stable reflex to pain stimulation by electric 
current was formed (Table 2). Thus, compari­
son of LP duration of I and II series determined 
increased time interval 2,8 times as much 1 
day after the first entrance of rats into a dark 
camera. On the 14th day this interval 2,5 times 
increased compared with the indices of I group. 
It should be noted that in comparison with the 
indices of II group LP 14 days later decreased 
reliably as well. Though, reliable difference 
with the index of I series was indicative of 
CRPA maintenance in the group of control dur­
ing all the periods of the experiment.
Further analysis of results was indicative 
of CRPA formation after electric­painful stimu­
lation of rats with type 2 DM (Table 2). 1 day 
later since the moment of electric current stim­
ulation LP 57,8 % increased. Though, deterio­
ration of memory of rats and CRPA inhibition 
on the 14th day after type 2 DM modeling was 
evidenced by 35,1 % reduced LP of entrance 
into a dark camera in comparison with the in­
dices of II series. At the same time, dynam­
Table 2
Effect of carbacetam and enalapril  
on the latent period of entrance to a dark camera of rats  
with type 2 diabetes mellitus in CRPA test, М±m
Latent period 
of entrance 
into the dark 
unit, с
Before carbacetam administration, І series
Control, n = 7 Diabetes mellitus, n = 21
61,14 ± 3,98 62,47 ± 2,59
1 day after carbacetam administration, ІІ series
Control, n = 7 Diabetes mellitus, n = 7
Diabetes mellitus + 
carbacetam, n = 7
Diabetes mellitus + 
enalapril, n = 7
170,71 ± 1,80* 98,57 ± 6,08# 123,14 ± 6,91#,** 119,14 ± 4,98#,**
14 days after carbacetam administration, ІІІ series
154,14 ± 6,52* 64,00 ± 6,25# 118,29 ± 7,39#,** 107,00 ± 7,98#,**
Reliability: 
* compared with the control of І series; 
# compared with the control of ІІ, ІІІ series;
** compared with simulated type 2 DM of ІІ, ІІІ series. 
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ics of changes in II and III series was char­
acterized by 42,3 and 58,5 % decreased LP in 
comparison with appropriate control indices. It 
proved the fact of a progressing deterioration of 
memory in rats with type 2 DM.
1 day after carbacetam and enalapril ad­
ministration LP of the entrance into a dark 
camera remained higher than that of the rats 
with type 2 DM of II series, and the difference 
was 25 and 21 % respectively. The obtained 
results were indicative of the ability of the 
exa mined pharmacological agents to improve 
cognitive activity under the experiment condi­
tions. The results of III series were indicative 
of probability of this suggestion. 14 days later 
after carbacetam and enalapril administration 
the dynamics of LP changes was characterized 
by increase of the indices 1,8 and 1,7 times as 
much in comparison with untreated rats.
AA analysis by Butler formula determined 
that the parameters under carbacetam effect 
are higher than those under enalapril effect 
both on the 1st and more on the 14th day (Fig. 1). 
At the same time, a considerable increase of 
AA in both groups on the 14th day of correc­
tion is indicative of an increasing effect after 
repeated (course) administration of GABA and 
ACEI modulator.
The obtained data concerning anti­amnes tic 
action are caused by the mechanism of action of 
the drugs. Nootropic action of carbacetam can 
be associated with the effect on GABA­ergic 
system [14], which modulation of the condi­
tion promotes improvement of cerebral circu­
lation and bioenergetic processes of the brain. 
Confirmation of this assumption is the infor­
mation [16] about the existence in the walls 
of the vessels of the system of synthesis and 
degradation of GABA, which plays a significant 
role in the regulation of cerebral circulation: 
expansion of cerebral vessels, increased blood 
flow, oxygenation and improvement of brain 
ener gy. In addition, carbacetam is modulated 
by GABAA­receptors — regulators of perme­
ability of chlorine channels in the CNS [12]. 
When the intracellular chlorine anion increas­
es, hyperpolarization occurs, neural communi­
cation and synchronization of neuronal popu­
lations are improved, and cognitive processes 
are activated [17]. It is possible that the cor­
rective effect of carbacetam on the prooxidant­
anti oxidant balance [8] is one of its protective 
mechanisms in the neurodegenerative proces­
ses of the CNS caused by type 2 diabetes.
Improvement of memory, cognitive and in­
tegral thinking activity against the ground of 
enalapril administration was caused by inhi­
bition of excessive activity under conditions of 
hyperglycemia effect and angiotensin II, which 
is a neurotoxin in its excessive amount [18]. 
Also, given the data on the regulatory role of 
cerebral RAS in learning and memory [19], im­
provement of cerebral blood supply is a leading 
mechanism of resistance to neurodegeneration. 
It is worth noting that the effect of RAS block­
ers is realized through peroxisome proliferator­
activated receptor­γ (PPARγ receptors), which 
are the central regulation of insulin and glu­
cose metabolism, which suppresses the progres­
sion of neurodegeneration, mediated by hyper­
Fig. 1. Anti­amnestic activity of rats with type 2 diabetes mellitus  
in the conditional reflex reaction of passive avoidance on the 1st and 14th day  
after carbacetam and enalapril administration.
57Проблеми ендокринної патології № 4, 2019
Клінічна ендокринологія
phosphorylation and tau phosphorylation is 
a mechanism of the neuroprotective action of 
enalapril [20].
Therefore, the analysis of the results indi­
cates the presence of rehabilitative effects of 
carbacetam and enalapril on cognitive function 
in rats in the absence of glucose­lowering ef­
fects in experimental neurodegeneration mode­
led on type 2 diabetes.
CONCLUSIONS
1. Behavior of rats with type 2 diabetes mel­
litus in «open field» test after carbacetam 
(5 mg/kg) and enalapril (1 mg/kg) adminis­
tration for 14 days is characterized by de­
crease of the latent period of «immobility», 
increased motor, oriented­learning activity, 
and is indicative of a prevailing action of car­
bacetam on reduction of anxiety level, im­
provement of adaptation and cognitive reac­
tions.  
2. After carbacetam administration for 14 days 
reduced grooming index is not resumed and 
the frequency of vegetative reactions — fecal 
boluses and defecations — is not changed, 
which is indicative of the lack of carbacetam 
effect on emotional level of rats with diabetes 
mellitus compared with enalapril improving 
emotional condition of rats. 
3. Increase of latent period of entrance into a 
dark camera on the 1st and 14th day of correc­
tion reflects maintenance of the conditional 
reflex reaction of passive avoidance to elect­
ric painful stimulation, and respectively — 
improvement of cognitive ability of rats with 
diabetes mellitus, mostly after administra­
tion of carbacetam than enalapril. 
4. In both groups with correction increased an­
ti­amnestic activity of rats was determined 
by means of Butler formula with dynamic 
increase of the index, mainly under carbace­
tam effect on the 14th day of the experiment.
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A progressive increase of complications of type 2 DM makes the problem very important for clinical and 
fundamental medicine. In particular, neurodegenerative processes in case of type 2 DM aggravate the course 
of the disease, change a usual life rhythm, and are a valuable cause of high rates of disability and lethality. 
Deterioration of cognitive functions is one of the main complications of diabetes. In certain literary sources 
inhibitors of angiotensin­transforming enzyme are considered as the means to prevent and treat complications 
of diabetes mellitus. Their role as modulators of gama­aminobutyric acid with development of central diabetic 
neurodegeneration is not completely determined yet.
Therefore, the objective of the study is to assess efficacy of pharmacological correction of cognitive disorders 
by carbacetam, a GABA modulator, and enalapril, a RAS blocker, in case of experimental neurodegeneration 
caused by type 2 DM.
Changes of the cognitive functions under carbacetam and enalapril effect in nonlinear laboratory albino 
male rats with neural degeneration under conditions of type 2 diabetes mellitus simulated by streptozotocin and 
high fat diet are studied.  The cognitive ability was assessed by behavioral reactions of rats in the tests «open 
field» and «the conditional reflex reaction of passive avoidance» by Butler formula. 
Behavior of rats with type 2 diabetes mellitus after administration of carbacetam and enalapril showed of 
cognitive functions in the groups. At the same time, carbacetam was found to possess better correcting effect on 
adaptation, cognitive reactions and anti­amnestic activity, while enalapril improved emotional condition of the 
rats mostly. Analysis of anti­amnestic properties found higher values of the parameters on the 14th day than on 
the 1st day of correction, which is indicative of the efficacy of a course administration of carbacetam and enala­
pril under conditions of neural degeneration stipulated by type 2 DM. 
K ey  wor d s :  type 2 diabetes mellitus, neurodegeneration, carbacetam, enalapril, cognitive ability of rats.
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Прогресивне зростання чисельності ускладнень цукрового діабету 2 типу робить проблему значу­
щою для клінічної та фундаментальної медицини. Зокрема, нейродегенеративні процеси при цукро­
вому діабеті 2 типу обтяжують перебіг захворювання, змінюють звичайний життєвий ритм, є вагомою 
причиною високих показників інвалідизації та летальності. Зниження когнітивних функцій є одним 
із основних ускладнень діабету. З літературних джерел відомо, що інгібітори ангіотензинперетво­
рювального ферменту розглядаються як засоби профілактики і лікування ускладненнях цукрового 
діабету, їх роль, як і модуляторів гама­аміномасляної кислоти, при розвитку центральної діабетичної 
нейродегенерації ще остаточно не визначена.
Тому метою роботи є оцінка ефективності фармакологічної корекції когнітивних порушень моду­
лятором гама­аміномасляної кислоти карбацетаму і блокатором ренін­ангіотензинової системи енала­
прилом при експериментальній нейродегенерації, спричиненої цукровим діабетом 2 типу.
Досліджено зміни когнітивних функцій під впливом карбацетаму та еналаприлу у нелінійних 
лабораторних білих щурів самців із нейродегенерацією за умов цукрового діабету 2 типу, змодельо­
ваного стрептозотоцином і високожировою дієтою. Когнітивну здатність оцінювали за поведінковими 
реакціями щурів у тестах «відкрите поле», «умовного рефлексу пасивного уникнення» та за формулою 
Баттлера. 
Оцінка поведінки у щурів із ЦД 2 типу показала покращення стану когнітивних функцій у гру­
пах із введенням карбацетаму та еналаприлу. Водночас мав місце переважний корегувальний вплив 
карбацетаму на адаптаційні, пізнавальні реакції та антиамнестичну активність, тоді як еналаприл 
більшою мірою покращував емоційний стан щурів. Аналіз антиамнестичних властивостей виявив 
більші значення показників на 14­ту, ніж на 1­шу добу корекції, що вказує на ефективність курсового 
введення карбацетаму та еналаприлу за умов нейродегенерації зумовленої ЦД 2 типу.
К л ю ч о в і  с л о в а :  цукровий діабет 2 типу, нейродегенерація, карбацетам, еналаприл, когнітивна 
здатність щурів.
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Прогрессивный рост численности осложнений сахарного диабета 2 типа делает проблему значи­
мой для клинической и фундаментальной медицины. В частности, нейродегенеративные процессы 
при сахарном диабете 2 типа отягощают течение заболевания, меняют обычный жизненный ритм, 
являются весомой причиной высоких показателей инвалидизации и летальности. Снижение когни­
тивных функций является одним из основных осложнений диабета. Из литературных источников 
известно, что ингибиторы АПФ рассматриваются как средства профилактики и лечения осложнениях 
сахарного диабета, их роль, как и модуляторов гамма­аминомасляной кислоты, при развитии цент­
ральной диабетической нейродегенерации еще окончательно не определена.
Поэтому целью работы является оценка эффективности фармакологической коррекции когни­
тивных нарушений модулятором гамма­аминомасляной кислоты карбацетамом и блокиратором ре­
нин­ангиотензиновой системы эналаприлом при экспериментальной нейродегенерации, вызванной 
сахарным диабетом 2 типа.
Исследованы изменения когнитивных функций под влиянием карбацетама и эналаприла в не­
линейных лабораторных белых крыс самцов с нейродегенерации при сахарном диабете 2 типа, смоде­
лированного стрептозотоцином и высокожировой диетой. Когнитивную способность оценивали по по­
веденческим реакциями крыс в тестах «открытое поле», «условного рефлекса пассивного избегания» 
и по формуле Баттлера.
Оценка поведения у крыс с СД 2 типа показала улучшение состояния когнитивных функций 
в группах с введением карбацетаму и эналаприла. В то же время имел место преимущественное кор­
ректирующий влияние карбацетаму на адаптационные, познавательные реакции и антиамнестиче­
ское активность, тогда как эналаприл в большей степени улучшал эмоциональное состояние крыс. 
Анализ антиамнестическое свойств обнаружил большие значения показателей к 14, чем на 1­е сутки 
коррекции, указывает на эффективность курсового введения карбацетаму и эналаприла в условиях 
нейродегенерации обусловленной СД 2 типа.
К л ю ч е в ы е  с л о в а :  сахарный диабет 2 типа, нейродегенерации, карбацетам, эналаприл, когни­
тивная способность крыс.
